Compare GBTG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | ACAD |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.3B |
| IPO Year | 2020 | 2000 |
| Metric | GBTG | ACAD |
|---|---|---|
| Price | $9.48 | $29.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 22 |
| Target Price | $8.92 | ★ $30.55 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | 69.12 |
| EPS | 0.13 | ★ 0.20 |
| Revenue | ★ $2,718,000,000.00 | $726,437,000.00 |
| Revenue This Year | $21.78 | $18.80 |
| Revenue Next Year | $4.29 | $11.70 |
| P/E Ratio | ★ $72.77 | $148.65 |
| Revenue Growth | 12.17 | ★ 40.45 |
| 52 Week Low | $4.96 | $19.69 |
| 52 Week High | $9.54 | $30.96 |
| Indicator | GBTG | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 57.27 |
| Support Level | $9.33 | $25.00 |
| Resistance Level | $9.51 | $30.96 |
| Average True Range (ATR) | 0.02 | 0.87 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 43.75 | 47.55 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.